Avidity Partners Management LP Apellis Pharmaceuticals, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $35.9 Million - $43.7 Million	468,700 New	468,700 $42.7 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $28.2 Million - $43.8 Million	629,000 Added 292.56%	844,000 $57.6 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $175,350 - $296,050	5,000 Added 2.38%	215,000 $9.72 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $7.45 Million - $11.4 Million	210,000 New	210,000 $10.7 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $31.6 Million - $44.4 Million	-774,000 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $4.64 Million - $8.62 Million	150,700 Added 24.18%	774,000 $44.3 Million
Q3 2020 Nov 16, 2020	BUY	$25.89 - $33.65 $16.1 Million - $21 Million	623,300 New	623,300 $18.8 Million

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.